MRI suspicious lesions in patients under active surveillance
Do systematic biopsies still add value?
DOI:
https://doi.org/10.5489/cuaj.9254Keywords:
Active Surveillance, Magnetic Resonance Imaging, prostate cancer;, Targeted biopsyAbstract
INTRODUCTION: Active surveillance (AS) requires regular monitoring to detect disease progression. Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsies are commonly used to identify clinically significant prostate cancer (csPC) in AS patients, yet their diagnostic value remains unclear among this population.
METHODS: We conducted a retrospective study of patients who underwent mpMRI followed by combined prostate biopsies between 2017 and 2022. Patients were categorized into AS and non-AS groups. We compared the diagnostic yield of mpMRI suspicious Prostate Imaging-Reporting & Data System (PI-RADS) 3-5 lesions using comparisons of PI-RADS score distribution and detection rates of csPC from targeted biopsies between the groups. Logistic regression was used to assess associations between AS category and outcomes. csPC detection rates of targeted and combined biopsies were also assessed.
RESULTS: The study consisted of 600 patients, 158 in the AS group and 442 in the non-AS group. PI-RADS score distribution and the number of suspicious lesions were similar between AS and non-AS groups. csPC detection rates from targeted biopsies were not different between AS and non-AS patients (32% vs. 30%, p=0.68), and AS was also not associated with the rates of csPC for each PI-RADS score. The addition of systematic biopsies did not increase csPC detection in AS patients (36% vs. 32%, p=0.47).
CONCLUSIONS: Our findings suggest that mpMRI suspicious PI-RADS 3-5 lesions are reliable for csPC diagnosis during AS, and that targeted biopsies alone may be sufficient for its detection; however, further prospective research is needed to validate these results and optimize biopsy strategies within AS protocols.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
